Aversive behavioural signs of morphine withdrawal in rats — a scored behavioural composite, not a physiological measurement.

Does this apply to people?

No. There is no human evidence, and precipitated withdrawal in rats does not reproduce the psychological and social dimensions of human dependence.

Selank (Tuftsin Analogue)

What an Aversive-Signs Model Measures

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Konstantinopolsky and colleagues reported in the Bulletin of Experimental Biology and Medicine in 2022 that Selank attenuated aversive signs of morphine withdrawal in rats — a behavioural endpoint scored in an animal model of induced dependence.

Key facts

Study: Konstantinopolsky 2022 (PMID 36322304)
Species: Rats
Model: Induced morphine withdrawal
Endpoint: Aversive behavioural signs
Reported: Attenuation of those signs
Human evidence: None

What the model does

Dependence is established in animals by repeated administration, then withdrawal is precipitated or allowed to occur. The resulting state produces a characteristic set of observable behaviours which are scored. It is a long-standing preclinical tool for studying the withdrawal state itself.

What aversive signs means

A defined list of behaviours counted or rated by observers over a set period. It is a behavioural composite rather than a physiological measurement, and its usefulness depends on consistent scoring, ideally by observers blind to treatment allocation.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

Why an enkephalin connection makes this a coherent question to ask

Selank's reported mechanisms include effects on enkephalin degradation, and enkephalins are endogenous opioid peptides. A compound touching opioid peptide handling being examined in an opioid withdrawal model is a mechanistically motivated experiment rather than an arbitrary screen.

Why attenuated is a limited claim

It means scored signs were less pronounced in treated animals than untreated ones. It does not mean withdrawal was prevented, that dependence was altered, or that any underlying process was reversed. It is a quantitative difference between groups on a behavioural composite in one model.

The distance from anything clinical

Precipitated withdrawal in rats is not a model of human dependence, which involves psychological, social and behavioural dimensions no animal model reproduces. Preclinical attenuation of withdrawal signs has been reported for many compounds over decades, and that history is one of poor translation.

What is explicitly not claimed

Nothing about dependence, withdrawal, opioids or addiction in any person. Selank holds no marketing authorisation anywhere, there is no human evidence in this context, and material supplied here is for laboratory research only. Nothing on this site is a treatment for anything, and dependence is a condition requiring proper clinical care.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What was measured?: Aversive behavioural signs of morphine withdrawal in rats — a scored behavioural composite, not a physiological measurement.
Why was Selank tested in this model?: Its reported mechanisms include effects on enkephalin degradation, and enkephalins are endogenous opioid peptides.
Does this apply to people?: No. There is no human evidence, and precipitated withdrawal in rats does not reproduce the psychological and social dimensions of human dependence.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum